Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of baxdrostat in adults with primary aldosteronism
CTR20253544Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary aldosteronism (PA) comparing Baxdrostat with Placebo (2 arms). Primary endpoint: Change from baseline in seated systolic blood pressure at Week 8. Started Dec 2025; status: active.
02
Drugs
baxdrostat
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on CTR20253544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253544.